Results 111 to 120 of about 60,894 (286)

Pediatric Post‐Vaccine Aluminum Granuloma: Morin Stain as a Diagnostic Aid

Journal of Cutaneous Pathology, EarlyView.
Justin R. Chang, Alvin Wong, Julio A. Diaz‐Perez, Chunyu Cai, Mark C. Mochel   +4 more
wiley   +1 more source

Global Authorship Representation in Otolaryngology Clinical Trials

Laryngoscope Investigative Otolaryngology, Volume 10, Issue 2, April 2025.
The clinical trial literature in the four most widely circulated OHNS journals is dominated by HIC authorship, with only marginal growth in LMIC contributions and no representation from LICs over the past two decades. This underrepresentation may impact the applicability of clinical guidelines in lower‐income regions.
Hong‐Ho Yang, Jeffrey D. Huynh, Clare Moffatt, Rolvix H. Patterson, Mary Jue Xu, Maie St. John   +5 more
wiley   +1 more source

Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France

Open Forum Infectious Diseases, 2016
Implementation of 13-valent conjugate pneumococcal vaccine in France has led to an overall antibiotic resistance decrease among invasive pneumococcal isolates.
C. Janoir, A. Lepoutre, L. Gutmann, E. Varon   +3 more
semanticscholar   +1 more source

Origins of T‐cell‐mediated autoimmunity in acquired aplastic anaemia

British Journal of Haematology, Volume 206, Issue 4, Page 1035-1053, April 2025.
Acquired aplastic anaemia (AA) is an autoimmune bone marrow failure disease caused by a cytotoxic T‐cell–mediated attack on haematopoietic stem and progenitor cells (HSPCs). Despite significant progress in understanding T‐cell repertoire alterations in AA, the identification of specific pathogenic T cells remains elusive.
Aura Enache, Shannon A. Carty, Daria V. Babushok   +2 more
wiley   +1 more source

Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with Chronic Disease

Emerging Infectious Diseases, 1999
To estimate the effectiveness of pneumococcal polysaccharide vaccine, we serotyped isolates submitted to the Pneumococcal Sentinel Surveillance System from 1984 to 1996 from 48 vaccinated and 125 unvaccinated children 2 to 5 years of age.
Anthony E. Fiore, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler   +4 more
doaj   +1 more source

Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa

PLoS ONE, 2017
Introduction Streptococcus pneumoniae is a leading cause of severe bacterial infections globally. A full understanding of the impact of pneumococcal conjugate vaccine (PCV) on pneumococcal disease burden, following its introduction in 2009 in South ...
C. von Mollendorf, S. Tempia, A. von Gottberg, S. Meiring, V. Quan, C. Feldman, J. Cloete, S. Madhi, K. O'Brien, K. Klugman, C. Whitney, C. Cohen   +11 more
semanticscholar   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology

Scientific Reports, 2017
There is growing concern that interventions that alter microbial ecology can adversely affect health. We characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial component of the ...
B. Kwambana-Adams, B. Hanson, A. Worwui, S. Agbla, Ebenezer Foster-Nyarko, Fatima Ceesay, Chinelo Ebruke, U. Egere, Yanjiao Zhou, Maze Ndukum, E. Sodergren, M. Barer, R. Adegbola, G. Weinstock, M. Antonio   +14 more
semanticscholar   +1 more source

Update on the success of the pneumococcal conjugate vaccine

Paediatrics & Child Health, 2011
Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Canada and elsewhere, routine infant vaccination has led to near eradication of invasive pneumococcal disease caused by vaccine serotype strains in both children and adults.
openaire   +3 more sources

Experience with pneumococcal conjugate vaccine in Norway

Expert Review of Vaccines, 2009
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly.
openaire   +3 more sources